Clinical Trials · NCT00902265

Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Name: Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ADesmopressin

Phase: N/A
Recruitment status: Completed
Sponsor: Ferring Pharmaceuticals
Enrollment: 138
Start date: Feb 2009
Locations: 140 sites, Germany
Primary endpoint: Overall Mean Change From Baseline in Mean Number of Nighttime Voids at Week 12

View Desmopressin compound reference